Lotte Keikes1, Martijn G H van Oijen2, Valery E P P Lemmens3, Miriam Koopman4, Cornelis J A Punt2. 1. Cancer Center Amsterdam, Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: l.keikes@amc.uva.nl. 2. Cancer Center Amsterdam, Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 3. Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 4. Department of Medical Oncology, University Medical Center, Utrecht, The Netherlands.
Abstract
BACKGROUND: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. PATIENTS AND METHODS: In all Dutch hospitals (n = 88) 1 medical oncologist involved in colorectal cancer care was approached to participate. An online survey was conducted regarding the local standard of care for adjuvant chemotherapy in high-risk stage II and stage III colon cancer and first-line treatment regimens in metastatic colorectal cancer. Frequency tables were provided for categorical variables and compared for differences in guideline adherence according to hospital type (academic/teaching/regional). RESULTS: The overall response rate was 70% (62 of 88). Reported guideline adherence was at least 60% of all presented settings. For high-risk stage II and stage III colon cancer, treatment strategies agreed with national guidelines in 66% and 84% of hospitals, and overtreatment patterns were identified in 28% and 13%, respectively. Targeted therapy was not routinely administered as first-line treatment in metastatic colorectal cancer (range from 63% to 71% in different settings). No differences in guideline adherence were observed among different hospital types. CONCLUSION: Guideline adherence as reported by medical oncologists in The Netherlands is suboptimal. Possible explanations include unawareness or disagreement with the guidelines, or local financial restrictions. Our results recommend additional support of guideline implementation and monitoring in clinical practice, and investigating underlying causes in case of nonadherence.
BACKGROUND: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. PATIENTS AND METHODS: In all Dutch hospitals (n = 88) 1 medical oncologist involved in colorectal cancer care was approached to participate. An online survey was conducted regarding the local standard of care for adjuvant chemotherapy in high-risk stage II and stage III colon cancer and first-line treatment regimens in metastatic colorectal cancer. Frequency tables were provided for categorical variables and compared for differences in guideline adherence according to hospital type (academic/teaching/regional). RESULTS: The overall response rate was 70% (62 of 88). Reported guideline adherence was at least 60% of all presented settings. For high-risk stage II and stage III colon cancer, treatment strategies agreed with national guidelines in 66% and 84% of hospitals, and overtreatment patterns were identified in 28% and 13%, respectively. Targeted therapy was not routinely administered as first-line treatment in metastatic colorectal cancer (range from 63% to 71% in different settings). No differences in guideline adherence were observed among different hospital types. CONCLUSION: Guideline adherence as reported by medical oncologists in The Netherlands is suboptimal. Possible explanations include unawareness or disagreement with the guidelines, or local financial restrictions. Our results recommend additional support of guideline implementation and monitoring in clinical practice, and investigating underlying causes in case of nonadherence.
Authors: Gabrielle Jongeneel; Thomas Klausch; Felice N van Erning; Geraldine R Vink; Miriam Koopman; Cornelis J A Punt; Marjolein J E Greuter; Veerle M H Coupé Journal: Int J Cancer Date: 2019-08-31 Impact factor: 7.316
Authors: Gabrielle Jongeneel; Marjolein J E Greuter; Felice N van Erning; Miriam Koopman; Geraldine R Vink; Cornelis J A Punt; Veerle M H Coupé Journal: Therap Adv Gastroenterol Date: 2020-09-16 Impact factor: 4.802
Authors: Florence Em de Rijk; Marinus A Kempeneers; Marco J Bruno; Marc Gh Besselink; Harry van Goor; Marja A Boermeester; Erwin Jm van Geenen; Jeanin E van Hooft; Hjalmar C van Santvoort; Robert C Verdonk Journal: United European Gastroenterol J Date: 2020-06-26 Impact factor: 4.623
Authors: Gabrielle Jongeneel; Marjolein J E Greuter; Felice N van Erning; Miriam Koopman; Geraldine R Vink; Cornelis J A Punt; Veerle M H Coupé Journal: Therap Adv Gastroenterol Date: 2021-03-12 Impact factor: 4.409
Authors: Zeta Chow; Tong Gan; Quan Chen; Bin Huang; Nancy Schoenberg; Mark Dignan; B Mark Evers; Avinash S Bhakta Journal: J Am Coll Surg Date: 2020-02-13 Impact factor: 6.532
Authors: E Aranda; E Polo; C Camps; A Carrato; E Díaz-Rubio; V Guillem; R López; A Antón Journal: Clin Transl Oncol Date: 2020-01-23 Impact factor: 3.405
Authors: Gabrielle Jongeneel; Marjolein J E Greuter; Felice N van Erning; Miriam Koopman; Jan P Medema; Raju Kandimalla; Ajay Goel; Luis Bujanda; Gerrit A Meijer; Remond J A Fijneman; Martijn G H van Oijen; Jan Ijzermans; Cornelis J A Punt; Geraldine R Vink; Veerle M H Coupé Journal: Eur J Health Econ Date: 2020-05-26
Authors: Michiel W H van Beek; Monique Roukens; Wilco C H Jacobs; Johanna N H Timmer-Bonte; Cees Kramers Journal: Drugs Real World Outcomes Date: 2018-09
Authors: Elske C Gootjes; Jaco Kraan; Tineke E Buffart; Lotte Bakkerus; Barbara M Zonderhuis; Cornelis Verhoef; Henk M W Verheul; And Stefan Sleijfer Journal: Cells Date: 2020-01-05 Impact factor: 6.600
Authors: Francisco Carrasco-Peña; Eloisa Bayo-Lozano; Miguel Rodríguez-Barranco; Dafina Petrova; Rafael Marcos-Gragera; Maria Carmen Carmona-Garcia; Josep Maria Borras; Maria-José Sánchez Journal: Int J Environ Res Public Health Date: 2020-09-14 Impact factor: 3.390